Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Breast Cancer
100%
Recurrent Disease
20%
BRCA1
20%
Methylation
19%
Diseases
15%
Neoplasm
14%
Intraductal Carcinoma
13%
Radiation Therapy
12%
Breast Carcinoma
12%
Chemotherapy
12%
Breast Radiotherapy
12%
Contralateral
11%
BRCA Mutation
11%
DNA Methylation
10%
Systemic Therapy
10%
Neoadjuvant Chemotherapy
10%
Stratifin
10%
Gamma Urogastrone
10%
Epidermal Growth Factor Receptor 2
10%
Metastatic Breast Cancer
10%
Hypercalcaemia
10%
Clinical Trial
10%
Malignant Neoplasm
9%
Mastectomy
9%
Tumor
9%
BRCA2
8%
Arm
8%
Calcitriol
7%
Cancer Cell
7%
Cyclin D2
7%
Hormone Therapy
6%
Thoracic Wall
6%
Magnetic Resonance Imaging
6%
Cancer
6%
Adjuvant Therapy
6%
Genetics
6%
Lymph Node
6%
Phase II Trials
5%
Germline Mutation
5%
Overall Survival
5%
Ductal Lavage
5%
Germ Cell
5%
Pericarditis
5%
Tight Junction Protein
5%
Polymyositis
5%
Letrozole
5%
Bladder
5%
Ascites
5%
Point Mutation
5%
Budd-Chiari Syndrome
5%
Keyphrases
Breast Cancer
57%
Trastuzumab
21%
Human Epidermal Growth Factor Receptor 2 (HER2)
19%
Hypermethylation
18%
BRCA2
18%
Paclitaxel
17%
Tumor
16%
Breast Tumor
15%
Metastatic Breast Cancer
15%
Ductal Carcinoma in Situ
15%
Promoter Methylation
14%
Chemotherapy
13%
Recurrence Score
12%
Radiation Therapy
12%
Cyclin D2 (CCND2)
12%
Breast Cancer Patients
11%
Early Events
11%
Stratifin
10%
Partial Breast Irradiation
10%
Homozygous Deletion
9%
Early Breast Cancer
9%
Hypercalcemia
8%
Breast Cancer Risk
8%
Germline mutation
8%
Quantitative Methylation-specific PCR (Q-MSP)
8%
BRCA-associated Breast Cancer
7%
Adjuvant Therapy
7%
Breast Cancer Cells
7%
Patients with Breast Cancer
7%
Calcitriol
7%
Locally Advanced Breast Cancer
6%
Taxanes
6%
Methylation Pattern
6%
BRCA mutation Carriers
6%
Contralateral Breast
6%
Gene Silencing
6%
Clinical Trials
6%
Tumor Characteristics
6%
Cowden Disease
5%
Expression Pattern
5%
Tumor-specific
5%
Systemic Therapy
5%
Chest Wall
5%
Breast Cancer Recurrence
5%
Breast Cancer Cases
5%
Clinical Outcomes
5%
Young Breast Cancer Survivors
5%
Pertuzumab
5%
Kallikrein 10
5%
Subjective Stress
5%
Biochemistry, Genetics and Molecular Biology
Methylation
60%
Promoter Region
34%
Cancer Cell
24%
DNA Methylation
18%
Tumor Suppressor Gene
14%
BRCA1
13%
Cyclin D2
12%
Genomics
12%
Germline Mutation
12%
Tumor Suppressor Protein
10%
Cohort Study
10%
Gene Inactivation
10%
Loss of Heterozygosity
9%
Messenger RNA
9%
Methylation Pattern
8%
Estrogen Receptor
7%
DNA Damage Response
7%
Carcinogenesis
7%
Gene Expression
6%
Epigenetic Regulation
6%
Normal Human
6%
Gene Mutation
6%
Coding Region
5%
Overall Survival
5%
Recurrence Free Survival
5%
Chromosome 10q
5%
Genetic Risk
5%
P53
5%
Microsatellite
5%
Arginine
5%
Claudin
5%
Somatic Mutation
5%
Point Mutation
5%
DNA Repair
5%
Trinucleotide Repeat Expansion
5%
Genetic Screening
5%
Wilms' Tumor
5%
Kallikrein
5%
Cancer Mortality
5%
RASSF1
5%
Stratifin
5%
Next Generation Sequencing
5%
